ExploreWatchlistsPricing
  1. JP-listed companies
  2. Kyowa Kirin Co.,Ltd.
  3. Financials
  4. Revenue growth (%)

Kyowa Kirin Co.,Ltd. (4151)

Market cap
¥1.26T
P/E ratio
16.7x
Kyowa Kirin manufactures and sells prescription pharmaceuticals through integrated operations from drug development to sales, serving healthcare markets globally.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue growth (%) YoY (%)
Dec 31, 20250.3-97.84%
Dec 31, 202412.1+9.54%
Dec 31, 202311-15.89%
Dec 31, 202213.1+22.91%
Dec 31, 202110.7+159.76%
Dec 31, 20204.1-134.89%
Dec 31, 2019-11.7+505.67%
Dec 31, 2018-1.9-164.24%
Dec 31, 20173-151.62%
Dec 31, 2016-5.8-163.17%
Dec 31, 20159.3-540.95%
Dec 31, 2014-2.1-193.75%
Dec 31, 20132.2-172.96%
Dec 31, 2012-3.1

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat